These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38974365)

  • 1. Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis.
    Shin H; Choi WM; Kim SU; Ko Y; Park Y; Park J; Hur MH; Park MK; Lee YB; Kim YJ; Yoon JH; Lee JH; Zoulim F
    JHEP Rep; 2024 Jul; 6(7):101089. PubMed ID: 38974365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
    Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
    BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
    J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
    Yip TC; Wong VW; Tse YK; Liang LY; Hui VW; Zhang X; Li GL; Lui GC; Chan HL; Wong GL
    Aliment Pharmacol Ther; 2021 Jan; 53(2):321-331. PubMed ID: 33222272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study.
    Chen YC; Jeng WJ; Hsu CW; Lin CY
    BMC Gastroenterol; 2020 May; 20(1):146. PubMed ID: 32397963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B.
    Hsiang JC; Wong GL; Chan HL; Chan AW; Chim AM; Wong VW
    Aliment Pharmacol Ther; 2014 Sep; 40(6):716-26. PubMed ID: 25039861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
    Jang H; Yoon JS; Park SY; Lee HA; Jang MJ; Kim SU; Sinn DH; Seo YS; Kim HY; Kim SE; Jun DW; Yoon EL; Sohn JH; Ahn SB; Shim JJ; Jeong SW; Cho YK; Kim HS; Nam JY; Lee YB; Kim YJ; Yoon JH; Zoulim F; Lampertico P; Dalekos GN; Idilman R; Sypsa V; Berg T; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Janssen H; Papatheodoridis GV; Lee JH
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1343-1353.e16. PubMed ID: 34500103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B.
    Huang YJ; Yang SS; Yeh HZ; Chang CS; Peng YC
    PLoS One; 2019; 14(8):e0221958. PubMed ID: 31469875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B.
    Wong GL; Chan HL; Yuen BW; Tse YK; Luk HW; Yip TC; Hui VW; Liang LY; Lee HW; Lui GC; Wong VW
    Liver Int; 2020 Mar; 40(3):549-557. PubMed ID: 31845462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Kim MA; Kim SU; Sinn DH; Jang JW; Lim YS; Ahn SH; Shim JJ; Seo YS; Baek YH; Kim SG; Kim YS; Kim JH; Choe WH; Yim HJ; Lee HW; Kwon JH; Lee SW; Jang JY; Kim HY; Park Y; Kim GA; Yang H; Lee HA; Koh M; Lee YS; Kim M; Chang Y; Kim YJ; Yoon JH; Zoulim F; Lee JH
    Gut; 2020 Dec; 69(12):2214-2222. PubMed ID: 32209606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B.
    Behera MK; Pati GK; Narayan J; Mishra D; Meher LK; Singh A; Uthansingh K; Sahu MK
    J Clin Exp Hepatol; 2021; 11(1):37-44. PubMed ID: 33679047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.